5.9k Share this

BioNTech has lifted its revenue forecast for its blockbuster coronavirus vaccine to €17bn this year as demand for the jab continues to grow.

The German biotech, which launched the first Covid-19 vaccine in partnership with US pharmaceutical company Pfizer, said on Tuesday that revenues would be €1bn higher than previously forecast.

The company said it expected to sell 2.5bn doses of the vaccine this year, after singing contracts for another 300m doses in the past three months. By the end of the year, it would have produced 3bn jabs, it said.

Shares in New York-listed BioNTech have risen 12 per cent on the news.

“We continue to work diligently to respond to global vaccine needs with a commitment to ensure equitable vaccine access,” said Ugur Sahin, the company’s chief executive, in a statement.

Demand for the jab had grown alongside regulatory approval in the US and Europe, he said, as well as the authorisation of booster shots in many countries. A recent spike in infections across Europe could fuel orders for boosters in the coming months.

The Mainz-based start-up’s fortunes soared after being the first company to bring to market a vaccine using messenger ribonucleic acid, or mRNA, technology. It was quickly followed by US rival Moderna.

In the past nine months, BioNTech has powered to €7.1bn in net profits, against net losses of €351m for the same period in 2020.

The company is funnelling much of its earnings into its oncology research. It said that it had spent €677m over the past three quarters, compared with €388m for the same period last year.

The company is researching personalised oncology treatment and has four different Phase 2 trials in development.

“We are reporting positive clinical data across six of our oncology programs at the upcoming SITC conference, including favourable safety profiles and robust immune responses,” Sahin said.

BioNTech, which reported a cash position of €2.39m for the third quarter, said it planned to further expand its research and development investments this year, but did not give any estimates.

In August, the company launched a trial for variant-specific versions of the coronavirus vaccine, but said that there was no clinical data yet to confirm the need for such jabs.

One of the trial candidates, which it is studying in a clinical trial alongside Pfizer, combines two variants of concern. The two companies are also looking at developing a vaccine that inoculates against both the coronavirus and influenza.

Source: This post first appeared on Duk News

5.9k Share this
You May Also Like

How Terra’s Algorithmic Stablecoin Came Crashing Down

Over the past week and a half, in one of the largest…

Tesla Autopilot’s Role in Deadly Vehicle Crash Is Probed by Safety Regulators

U.S. auto-safety regulators have opened a special crash investigation into a fatal…

Liam Payne shares a glimpse of ‘£300,000’ performance at a billionaire’s birthday bash

Liam Payne took to Instagram on Wednesday after a week’s sabbatical to…

The Battle Between Long And Short

From the outside Netflix and TikTok may not look like competitors, but…

Zelensky quotes from Charlie Chaplin’s 1940 film about Hitler at Cannes

Ukrainian President Volodymyr Zelensky has addressed the Cannes Film Festival and called…

Singer Kiesza backs robot NFT to give prosthetic limbs to a young man and a dog

In a positive twist for the nonfungible token (NFT) mania, Canadian singer…

There Will Be ‘High-Level Prosecutions of People Close to Donald Trump’

On Thursday, during MSNBC’s “All In,” former Attorney General Eric Holder predicted…

Recent Transfer Rumours Demonstrate The Beast In Juventus Has Been Reawakened

Paris Saint-Germain’s Argentine midfielder Angel Di Maria celebrates scoring his team’s third…